Table 1. Clinicopathological characteristics, overall survival (OS), KRAS mutational status and metastatic pattern in lung adenocarcinoma patients.
| Metastatic site | Total | Single-organ | Multiple-organ | Lung* | Bone* | Adrenal* | Brain* | Pleura* | Liver* | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of patients | 500 | 362** | 138 | 228 | 131 | 87 | 84 | 78 | 55 | |
| Single-organ only | 152 | 50 | 38 | 53 | 43 | 16 | ||||
| Age (mean ± SD) | 61.9 ± 9.4 | 62.3 ± 9.3 | 60.8 ± 9.7 | 62 ± 8.9 | 60 ± 10.7 | 63.1 ± 6.8 | 59.7 ± 9.2 | 66.8 ± 10.4 | 64.4 ± 9.1 | |
| Gender | Male | 245 (49%) | 181 (50%) | 64 (46%) | 102 (45%) | 74 (56%) | 34 (39%) | 36 (43%) | 38 (49%) | 26 (47%) |
| Female | 255 (51%) | 181 (50%) | 74 (54%) | 126 (55%) | 57 (44%) | 53 (61%) | 48 (57%) | 40 (51%) | 29 (53%) | |
| ECOG PS | 0–1 | 459 (94%) | 335 (94%) | 124 (92%) | 218 (97%) | 115 (91%) | 75 (87%) | 77 (93%) | 71 (91%) | 48 (91%) |
| >1 | 32 (6%) | 21 (6%) | 11 (8%) | 7 (3%) | 11 (9%) | 11 (13%) | 6 (7%) | 7 (9%) | 5 (9%) | |
| Unknown | 9 | 6 | 3 | 3 | 5 | 1 | 1 | 0 | 2 | |
| Smoking | Never | 67 (15%) | 52 (16%) | 15 (12%) | 29 (14%) | 18 (16%) | 7 (9%) | 7 (9%) | 20 (27%) | 4 (8%) |
| Former | 141 (31%) | 104 (31%) | 37 (30%) | 61 (29%) | 32 (28%) | 20 (25%) | 25 (32%) | 23 (32%) | 20 (41%) | |
| Current | 250 (54%) | 179 (53%) | 71 (58%) | 117 (57%) | 65 (58%) | 52 (66%) | 45 (58%) | 30 (41%) | 25 (51%) | |
| Unknown | 42 | 27 | 15 | 21 | 16 | 8 | 7 | 5 | 6 | |
| KRAS | Wild-type | 357 (71%) | 263 (73%) | 94 (68%) | 148 (65%) | 94 (72%) | 58 (67%) | 60 (71%) | 65 (83%) | 46 (84%) |
| Mutant | 143 (29%) | 99 (27%) | 44 (32%) | 80 (35%) | 37 (28%) | 29 (33%) | 24 (29%) | 13 (17%) | 9 (16%) | |
| ***Median OS (months) | 10.8 | 11.67 | 6.87 | 15.6*** | 7.9*** | 14.4*** | 10.3*** | 8.8*** | 8.9*** | |
*Values include both single- and multiple-organ cases except for OS. **In 10 cases, other than the listed types of metastasis was present (renal and subcutaneous). ***Only single-organ metastatic patients were included. Data shown in parentheses are column percentages; ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival.